Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. - Shah,M.A.; Ramanathan,R.K.; Ilson,D.H. (J Clin Oncol, 2006)